Paper32246720
SynergyFinder 2.0: visual analytics of multi-drug combination synergies.
Ianevski A and 2 others. Nucleic Acids Res, 2020. Cited by 692 papers, by iCite.
Cite this record
ConductScience Library. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Papers, record 32246720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32246720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Synergism | Major topic |
| Drug Therapy, Combination | Major topic |
| Software | Major topic |
| Computer Graphics |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 35713562 | Correction to 'SynergyFinder 2.0: visual analytics of multi-drug combination synergies'. | https://conductscience.org/library/papers/35713562 |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32012154 | SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. | PLoS Comput Biol | 2020 | https://conductscience.org/library/papers/32012154 | PubMed |
| 2 | 29026882 | Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. | Sci Adv | 2017 | https://conductscience.org/library/papers/29026882 | PubMed |
| 3 | 29483097 | Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. | Cancer Res | 2018 | https://conductscience.org/library/papers/29483097 | PubMed |
| 4 | 26355399 | A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. | Sultan Qaboos Univ Med J | 2015 | https://conductscience.org/library/papers/26355399 | PubMed |
| 5 | 31287813 | Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. | PLoS Med | 2019 | https://conductscience.org/library/papers/31287813 | PubMed |
| 6 | 31734160 | Emergent Gene Expression Responses to Drug Combinations Predict Higher-Order Drug Interactions. | Cell Syst | 2019 | https://conductscience.org/library/papers/31734160 | PubMed |
| 7 | 26171228 | Analysis of drug combinations: current methodological landscape. | Pharmacol Res Perspect | 2015 | https://conductscience.org/library/papers/26171228 | PubMed |
| 8 | 25157754 | Computational tools for fitting the Hill equation to dose-response curves. | J Pharmacol Toxicol Methods | 2015 | https://conductscience.org/library/papers/25157754 | PubMed |
| 9 | 30596642 | Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment. | PLoS Comput Biol | 2018 | https://conductscience.org/library/papers/30596642 | PubMed |
| 10 | 31518641 | Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls. | Drug Discov Today | 2019 | https://conductscience.org/library/papers/31518641 | PubMed |
| 11 | 30392419 | Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. | Expert Rev Anti Infect Ther | 2018 | https://conductscience.org/library/papers/30392419 | PubMed |
| 12 | 12829555 | Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. | BMJ | 2003 | https://conductscience.org/library/papers/12829555 | PubMed |
| 13 | 28338065 | Prospects for combining targeted and conventional cancer therapy with immunotherapy. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/28338065 | PubMed |
| 14 | 30777010 | Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets. | BMC Bioinformatics | 2019 | https://conductscience.org/library/papers/30777010 | PubMed |
| 15 | 24613352 | Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. | Cell Rep | 2014 | https://conductscience.org/library/papers/24613352 | PubMed |
| 16 | 28446463 | The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. | Cancer Res | 2017 | https://conductscience.org/library/papers/28446463 | PubMed |
| 17 | 28379339 | SynergyFinder: a web application for analyzing drug combination dose-response matrix data. | Bioinformatics | 2017 | https://conductscience.org/library/papers/28379339 | PubMed |
| 18 | 27562164 | Prediction of multidimensional drug dose responses based on measurements of drug pairs. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27562164 | PubMed |
| 19 | 31575655 | Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/31575655 | PubMed |
| 20 | 31594982 | Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines. | Sci Rep | 2019 | https://conductscience.org/library/papers/31594982 | PubMed |
Cited by534
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 692 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42948370 | Identification of FDA-approved IMPDH inhibitors boosting the broad-spectrum antiviral potential of ribavirin through depleting cellular GTP pool. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42948370 | PubMed |
| 42919347 | ComplexMatrixComb: predicting anticancer drug combination dosages for target growth inhibition via complex-number matrix factorization. | J Cheminform | 2026 | https://conductscience.org/library/papers/42919347 | PubMed |
| 42889628 | Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells. | ACS Omega | 2026 | https://conductscience.org/library/papers/42889628 | PubMed |
| 42875447 | Multi-omics profiling identifies triciribine as a biomarker-guided antimetabolite therapy for acute lymphoblastic leukemia. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42875447 | PubMed |
| 42815467 | EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42815467 | PubMed |
| 42797238 | Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797238 | PubMed |
| 42796579 | GC-MS Profiling, Antioxidant and Enzyme Inhibitory Activities of Basil (Ocimum basilicum L.) and Clove (Syzygium aromaticum L.) Essential Oils and Their Binary Mixtures. | Molecules | 2026 | https://conductscience.org/library/papers/42796579 | PubMed |
| 42660974 | Cheminformatic identification of small molecules targeting acute myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/42660974 | PubMed |
| 42656441 | Eupatilin-derived compounds enhance antitumor activity and doxorubicin efficacy in triple-negative breast cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42656441 | PubMed |
| 42625328 | CDK12/13 Inhibition Induces DNA Hypomethylation and Sensitizes Cancer Cells to Compounds Targeting DNA-PK. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42625328 | PubMed |
| 42618565 | Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42618565 | PubMed |
| 42605598 | Lignin Mimicking Protein Methylation Augments the Efficacy of FOLFOX Chemotherapy by Anchoring Thymidylate Synthase. | Adv Mater | 2026 | https://conductscience.org/library/papers/42605598 | PubMed |
| 42550688 | The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages. | Cell Rep | 2026 | https://conductscience.org/library/papers/42550688 | PubMed |
| 42515757 | Angelica sinensis as a Multi-Targeted Natural Product Candidate: Constituent-Specific Mechanisms, Exposure Constraints, and Translational Development Challenges. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42515757 | PubMed |
| 42493737 | Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery. | Chem Biol Drug Des | 2026 | https://conductscience.org/library/papers/42493737 | PubMed |
| 42493544 | Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer. | Oncogene | 2026 | https://conductscience.org/library/papers/42493544 | PubMed |
| 42484926 | Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin. | Med Oncol | 2026 | https://conductscience.org/library/papers/42484926 | PubMed |
| 42448681 | Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42448681 | PubMed |
| 42303049 | Drug combination treatment as a strategy for inhibiting human adenovirus replication. | Antiviral Res | 2026 | https://conductscience.org/library/papers/42303049 | PubMed |
| 42294111 | From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42294111 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32246720
GET https://conductscience.org/api/papers/v1/32246720/references?page=2